Viswam Nair, MD
Pulmonary Disease · Berkeley, CANPI 1336336460
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Roche Sequencing Solutions, Inc. at 38.4% of the total. Reporting peaked in 2020 at $1,553 and has fallen 81.5% since, to $287 in 2025.
Across 15 payments — averaging $260.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Sequencing Solutions, Inc.$2K
- Verathon Inc.$1K
- Johnson & Johnson$747
- AstraZeneca$122
- Veran Medical Technologies, Inc.$112
- Medtronic$65
- plus $111 from 4 others
Across 3 payments — averaging $66,773 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diagnostics Corporation$200K
What the payments were for
- Consulting fees$1,25032%
- Speaking & faculty fees$1,50038%
- Travel & lodging$74719%
- Food & beverage$41010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Sequencing Solutions, Inc. | 1 | $1,500 |
| Verathon Inc. | 1 | $1,250 |
| Johnson & Johnson | 1 | $747 |
| AstraZeneca | 4 | $122 |
| Veran Medical Technologies, Inc. | 2 | $112 |
| Medtronic | 1 | $65 |
| GSK | 2 | $48 |
| Sanofi | 1 | $36 |
| Philips North America LLC | 1 | $16 |
| Adaptive Biotechnologies Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SEQUENCING RESEARCH & DEVELOPMENT$1,500
- NPD Clinical Study$1,250
- MONARCH$747
How this compares
$3,907 in reported general payments places this provider in the 65th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Berkeley
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.